

JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.*(Public Sector Undertaking of Govt of Jammu & Kashmir)*

Corporate Head Office: Plot No: 58, Friends Colony, Satyam Road, Trikuta Nagar Jammu

Corporate Office: Opp State Motor Garages Near Haj House, Bemina, Srinagar

Telephone: 0191-2580842, Fax: 0191-2581845 (Jammu); Telefax: 0194-2432008 (Srinagar)

Telefax: 0194-2432008 email: gmjkkmscl@gmail.com; website: www.jkmscl.nic.in

JKMSCL**::NOTIFICATION::**

JKMSCL has issued tender for procurement of **"Allopathic Drugs/ Medicines"** Uploaded vide No: JKMSCL/Drugs & Medicines/2024/613 Dated: 05-02-2023. Following items are claimed to be propriety/patented products of the manufacturers mentioned against each bidder:

S. No	Item Code	Name of Item	Bidder	Name of Manufacturer claiming Proprietary/ Patented
1.	1843	Pertuzumab+ Trastuzumab Injection 600mg+600mg in 10 ml	M/s Roche Products Pvt.. Ltd Mumbai	M/s F. Hoffmann-La Roche Ltd Switzerland
2.	1844	Pertuzumab + Trastuzumab Injection 1200mg/600mg in 15ml		M/s Roche Diagnostics GmbH, Germany
3.	1862	Atezolizumab Injection 1200 mg/ 20 ml		
4.	1863	Obinutuzumab Injection 1000mg/ 40 ml		
5.	1879	Pertuzumab Injection 420 mg/14 ml		
6.	1890	AvelumabInjection 200mg/ 10 ml	Merck Specialties Pvt.. Ltd Mumbai	M/s Merck Serono, Switzerland
7.	1891	CetuximabInjection 100mg/20ml (5mg/ml)		M/s Merck Healthcare KGaA Germany
8.	1892	Cetuximab Injection500mg/100ml		M/s Merck SeronoS.p.A Italy
9.	1899	Recombinant FSH Injection 450 IU/ 0.75 ml		
10.	1881	Nivolumab Injection 10 mg/ ml, 40mg	Bristol Myers Squibb India Pvt. Ltd Mumbai	M/s Bristol Myers Squibb Holdings Pharma Ltd U.S.A
11.	1882	Nivolumab Injection 10 mg/ml, 100mg		M/s Patheon Italia. S.p.A Italy
12.	1889	Ipilimumab Injection 50mg/ 10 ml		
13.	1883	Luspatercept Injection 25mg/Vial		
14.	1884	Luspatercept Injection 75mg/Vial		
15.	1864	Alteplase InjectionEP 20mg	Boehringer Ingelheim India Pvt. Ltd Mumbai	M/s BoehringerIngelheimPharma GmbH &Co.Kg.
16.	1865	Alteplase InjectionEP 50mg		
17.	1866	Empagliflozin 25mg Tab.		
18.	1867	Empagliflozin/Linagliptin 25mg+ 5mg Tab.		
19.	1726	Human Coagulation Factor-X 250-IU/vial.	Alpha Drugs New Delhi	M/s Bio Products Laboratory (BPL) Ltd United Kingdom
20.	1816	Fentanyl Transdermal Patch 50 mcg/hr	Jhonson and	M/s JanssanPharmaceutica NV, Belgium
21.	1829	DaratumumabInjection 100mg/5 ml	Jhonson Pvt. Ltd Mumbai	M/s Cilag AG, Hochstrasse, Switzerland
22.	1830	Daratumumab Injection 400mg/ 20 ml		
23.	1846	Golimumab Auto Injector 50mg/ 0.5ml		
24.	1847	Ustekinumab Infusion Injection		

h

5/7

		130mg/26ml		
25.	1848	Ustekinumab Injection 90 mg/ml		
26.	1851	Ibrutinib 140 mg		
27.	1854	Amivantamab Injection 350mg/7ml		
28.	1735	Inj. Risperidone long acting 25mg/2ml		
29.	2048	Inj. Mepolizumab 100mg	Glaxo SmithKline Pharmaceuticals Ltd Mumbai	M/s Galaxy Operations U.K
30.	2033	Herpes Zoster Vaccine (Recombinant, Adjuvanted)	Glaxo SmithKline Pharmaceuticals Ltd Mumbai	M/s Galaxosmithkline S.A, Belgium
31.	2020	Lorlatinib Tab. 25mg	Pfizer Products India Pvt. Ltd Mumbai	Pfizer Manufacturing Deutschland GmbH Germany
32.	2021	Lorlatinib Tab. 100 mg		
33.	2022	Crizotinib Cap. 250 mg		
34.	2023	Dacomitinib Tab. 30 mg		
35.	2026	Inotuzumab Ozogamicin Injection 1mg/ Vial		Pharmacia and Upjohn company LLC United States
36.	2040	Dexketoprofen 25mg + Paracetamol 325 mg	Sam Pharma Co. Ltd. H.P	Emcure Pharmaceuticals Limited Jammu
37.	1871	Desidustat Tab. 100mg	New India Medicine House Jmu	M/s Zydus Life Sciences Ltd Gujarat
38.	1901	Desidustat Tab 25mg		
39.	1902	Desidustat Tab 50mg		
40.	1839	Tagafur + Gimeracil + Oteracil, Cap. 20mg+5.8mg+15.8mg	M/S BDR Pharmaceutic als Pvt. Ltd. Mumbai	Patented claimed by M/S BDR Pharmaceuticals Pvt. Ltd. Mumbai
41.	1840	Tagafur + Gimeracil + Oteracil, Cap. 15mg+4.35mg+11.8mg		
42.	1958	Fosfomycin Sodium Inj. 4 g		
43.	1969	Eltrombopag Olamine Tab. 50 mg		
44.	2059	Inj. Sugammadex 200mg/2ml		

It is notified that in case any bidder / manufacturer/ importer have any objections / comments related to above mentioned Items in terms of Proprietary /Patent of the mentioned items, as claimed by the Bidders please reply with proper justification/documents through e-mail on mdjkmscl2@gmail.com / gmkjkmscl1@gmail.com within 4 days from the date of issuance of this notification. Thereafter no objection shall be entertained.

[Signature]
6/7/2024
General Manager (Drugs)
JKMSCL

No.: JKMSCL/Drugs/613/2024/4897-4900 Dated: 06-07-2024

Copy for information to the:

- 1 Managing Director, JKMSCL
- 2 Financial Advisor /Chief Account Officer, JKMSCL.
- 3 General Manager (Adm) JKMSCL
- 4 I/c Website to upload the notification on the official website of JKMSCL.
- 5 Office Record.